Read insightful articles and thought leadership from Shilpa Medicare on pharmaceutical innovation, drug delivery technologies, industry trends, regulatory updates, and healthcare advancements.
This is where Shilpa Medicare's own scientists share technical perspective on Active Pharmaceutical Ingredient manufacturing, complex generic development, biosimilars, antibody-drug conjugates, peptide synthesis and pharmaceutical regulatory affairs — first-hand, named-author writing for sourcing managers, technical evaluators and researchers who need a real answer rather than a marketing page.
Authored by named Shilpa Medicare scientists with their credentials, covering API manufacturing, complex generics, biosimilars and ADC development.
Anonymised CDMO programme outcomes — timelines compressed, yields improved, filings achieved.
Deep technical documents published quarterly, freely accessible without registration.
Facility walkthroughs, platform explainers and scientist interviews.
ADC Development and Manufacturing: Integrating Payload, Linker, Antibody and Conjugation
PeptidesPeptide CDMO: From Route Design to Commercial-Scale Manufacturing
HPAPIHigh-Potency API Manufacturing: The Role of Containment, Process Safety and Analytical Control
FermentationLarge-Scale Microbial Fermentation: From Strain Development to Commercial Production
BiosimilarsBiosimilar Development: Why Analytical Characterization Is Central to Comparability
Recombinant ProteinsRecombinant Human Albumin: Moving Beyond Plasma-Derived Supply
PolymersSpecialty Polymers in Pharmaceutical Development: Designing Materials for Performance
Drug DeliveryAdvanced Drug Delivery: From Conventional Dosage Forms to Patient-Centric Technologies
Quality by DesignQbD in Pharmaceutical Development: Building Quality into the Process
CDMO PartnershipsFrom API Development to Commercial Supply: What Makes a Successful CDMO Partnership?
BioprocessingContinuous Bioprocessing: Improving Productivity and Process Consistency in Biologics
Regulatory StrategyRegulatory Strategy as a Development Tool — From CMC to Global Filing
Every article carries a named author with their qualifications and role — never an unattributed byline — and is technically reviewed before publication, with the reviewer's name, title and review date shown alongside a visible last-updated date. Wherever possible, our articles cite primary sources: FDA DMF listings, the EDQM CEP database, USP/EP monographs and peer-reviewed literature. Nothing here is gated behind a registration form.
For press inquiries:
media@vbshilpa.com
+91 8532 238704
